A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

被引：0

作者：

Mark D. DeMario

Mark J. Ratain

Nicholas J. Vogelzang

Sridhar Mani

Everett E. Vokes

Gini F. Fleming

Kimberly Melton

Sheryl Johnson

Steven Benner

David Lebwohl

机构：

[1] Section of Hematology/Oncology,

[2] Department of Medicine,undefined

[3] The University of Chicago,undefined

[4] Medical Center,undefined

[5] Chicago,undefined

[6] IL,undefined

[7] USA,undefined

[8] Committee on Clinical Pharmacology and Cancer Research Center,undefined

[9] The University of Chicago Medical Center,undefined

[10] 5841 S. Maryland Avenue,undefined

[11] MC2115,undefined

[12] Chicago,undefined

[13] IL 60637-1470,undefined

[14] USA Tel.: +1773-702-4400; Fax: +1-773-702-0963,undefined

[15] Bristol Myers Squibb Pharmaceutical Research Institute,undefined

[16] Richard L Gelb Center for Pharmaceutical Research and Development,undefined

[17] 5 Research Parkway,undefined

[18] P.O. Box 5100 Wallingford,undefined

[19] CT 06492-7660,undefined

[20] USA,undefined

来源：

Cancer Chemotherapy and Pharmacology | 1999年 / 43卷

关键词：

Key words Oral chemotherapy; JM-216; UFT; Hyperemesis; Advanced cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Purpose: To determine the feasibility, maximal tolerated doses, and response rates for a combined regimen of the platinum and 5-fluorouracil oral analogues bis-acetato-ammine-dichloro-cyclohexyl-amine platinum(IV) (JM-216) and uracil/ftorafur (UFT) coadministered as a 14 consecutive-day every 28-day schedule. Methods: Of 20 patients enrolled in this investigation, 17 on the following dose escalation scheme were evaluable for toxicity and/or response: I UFT 300 mg/day, JM-216 5 mg/day (three patients), II UFT 300 mg/day, JM-216 10 mg/day (four patients), III UFT 300 mg/day, JM-216 20 mg/day (ten patients). Results: All 17 evaluable patients were evaluable for toxicity. At dose level III, dose-limiting nausea and emesis were observed in one patient despite maximal antiemetic support. Importantly, neurotoxicity and nephrotoxicity were not observed at the JM-216 dose levels examined in this study. This observation is consistent with results seen with single agent JM-216. Conclusion: For JM-216 and UFT administered at 20 mg/day and 300 mg/day over 14 days, nausea and emesis were observed as the principal dose-limiting toxicities. These doses are considerably below the maximally tolerated doses of single agent JM-216 and UFT. Shorter administration schedules should be explored in an attempt to increase the dose intensity and minimize the toxicity of this combination oral regimen.

引用

页码：385 / 388

页数：3